Recent clinical trials demonstrating the efficacy of an MR antagonist in slowing down the progression of renal dysfunction in type 2 diabetes support the exploration of miRNAs associated with aldosterone signaling and MR activation as potential novel therapeutic targets for DKD. Here, NR3C2 is linked to diabetic kidney disease.